Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug 1;18(1):127.
doi: 10.1186/s13014-023-02302-8.

Long-term outcomes of SBRT for PSMA PET detected oligometastatic prostate cancer

Riche Mohan  1   2 , A Kneebone  3   4 , T Eade  3   4 , E Hsiao  3   4 , L Emmett  3   4   5 , Christopher Brown  3   4 , J Hunter  3   4 , G Hruby  3   4
Affiliations

Long-term outcomes of SBRT for PSMA PET detected oligometastatic prostate cancer

Riche Mohan et al. Radiat Oncol. .

Abstract

Background: Oligometastatic disease in prostate cancer (PCa) is a challenging clinical scenario encountered more frequently with the widespread adoption of PSMA-PET. SBRT aims to defer androgen deprivation and may deliver sustained biochemical failure (BF) free survival in selected patients. Little long-term data is currently available regarding the effectiveness of this approach.

Methods: A retrospective single institution study of PSMA-PET directed SBRT without initial ADT for oligo-metachronous PCa. Median dose/fractionation was 24 Gy in 2# to bones and 30 Gy in 3# to lymph nodes. The primary endpoint was time to BF (PSA + 0.2 ug/L above nadir). Secondary endpoints included time to ADT for relapse (i.e. palliative ADT), BF defined as PSA nadir + 2 ug/L, toxicity, patterns of failure and survival. Patients were excluded if they received ADT with their SBRT, had short disease-free interval, or > 3 metastases on PSMA-PET.

Results: 103 patients treated from November-2014 to December-2019 were analysed from our prospective database. Median follow-up was 5 years. 64 patients were treated for nodal only disease, 35 bone only and 4 mixed. 15% were free of any BF at 5 years with median time to BF of 1.1 years. 32% (33/103) of patients had further curative-intent radiation treatment following their first BF after SBRT, including subsequent SBRT. Eight patients underwent potentially curative treatment for their second or third relapse. Allowing for salvage treatment, 29/103 (28%) were biochemically disease free at last follow up. At 5 years, 39% of patients had never received any ADT and 55% had not started ADT for relapse with a median time to ADT for relapse of 5.5 years. There were 2 grade 3 toxicities (rib fracture and lymphoedema), and no local failures.

Conclusion: PSMA-PET guided SBRT for oligo-metachronous PCa recurrence in appropriately triaged patients results in excellent local control, low toxicity and over 50% ADT free at 5 years.

PubMed Disclaimer

Conflict of interest statement

None.

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
PSA Response to SBRT
Fig. 2
Fig. 2
Time to Biochemical failure (A) defined as nadir + 0.2 (B) defined as nadir + 2
Fig. 3
Fig. 3
Time to ADT failure (A) ADT for Relapse (B) any ADT
Fig. 4
Fig. 4
Cohort outcomes
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. van Leeuwen PJ, et al. (68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment. BJU Int. 2016;117(5):732–9. doi: 10.1111/bju.13397. - DOI - PubMed
    1. Morigi JJ, et al. Prospective comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in prostate Cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J Nucl Med. 2015;56(8):1185–90. doi: 10.2967/jnumed.115.160382. - DOI - PubMed
    1. Decaestecker K, et al. Surveillance or metastasis-directed therapy for OligoMetastatic prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial. BMC Cancer. 2014;14:671. doi: 10.1186/1471-2407-14-671. - DOI - PMC - PubMed
    1. Kneebone A, et al. Stereotactic body radiotherapy for oligometastatic prostate Cancer detected via prostate-specific membrane Antigen Positron Emission Tomography. Eur Urol Oncol. 2018;1(6):531–7. doi: 10.1016/j.euo.2018.04.017. - DOI - PubMed
    1. Azzam G, et al. SBRT: an opportunity to improve quality of life for oligometastatic prostate Cancer. Front Oncol. 2015;5:101. doi: 10.3389/fonc.2015.00101. - DOI - PMC - PubMed

MeSH terms

Substances